Smith & Nephew launches JOURNEY™ II Cruciate Retaining natural-motion knee replacement at AAOS annual meeting

  Smith & Nephew launches JOURNEY™ II Cruciate Retaining natural-motion knee
                      replacement at AAOS annual meeting

PR Newswire

LONDON, March 12, 2014

LONDON, March 12, 2014 /PRNewswire/ -- Smith & Nephew (LSE:SN NYSE:SNN), the
global medical technology business, announces the launch of the JOURNEY™ II
Cruciate Retaining (CR) knee replacement at the American Academy of
Orthopaedic Surgeons (AAOS) meeting in New Orleans today. The new implant
extends the JOURNEY II Total Knee System to procedures that preserve the
posterior cruciate ligament (PCL), which accounts for approximately half of
all knee replacement procedures.

Smith & Nephew logo

The JOURNEY II CR knee, like the JOURNEY II Bi-cruciate Stabilized (BCS) knee
that was launched at last year's AAOS meeting, sets a new standard inknee
implant performanceby restoring more normal motion for patients. This is
achieved through the reproduction of both the shapesof the joint's hard
surfacesand the normal force behavior of the soft tissues, such as ligament
and muscle firing patterns. As a result, the soft tissue's readjustment to new
shapes and forces after surgery is minimized, helping to return the patient's
stride to its natural motion.^1

"Access to this next-generation technology has been remarkable for my
practice," said Jeff Geller, MD, of Columbia Presbyterian Hospital in New
York. "I choose a cruciate retaining knee replacement whenever possible for my
patients, and this is the first time I've been confident they're receiving a
device that's kinematically correct. Most importantly, my patients confirm
this in our follow-up discussions."

The JOURNEY II CR knee is the first PCL-sparing total knee replacement
designed to provide normal kinematics and increased patient satisfaction
through PHYSIOLOGICAL MATCHING™ Technology. This innovative approach to
implant development uses the company's LIFEMOD™ human simulation software to
analyze the bone, ligament and muscle forces that impact the knee, and then
account for those forces within the design of an implant intended to help
restore anatomic shapes and normal motion.

"The JOURNEY II CR knee will be a key component of our total knee replacement
portfolio," said Gaurav Agarwal, President, Orthopaedic Reconstruction, Smith
& Nephew. "The unique patient benefits of the JOURNEY II BCS knee have made it
among the most popular implants we've ever introduced, and since our customers
choose a PCL-sparing device in approximately one-half of knee replacement
cases, we expect the new JOURNEY II CR to further drive adoption of the
JOURNEY II system."

The JOURNEY II CR knee is made from Smith & Nephew's VERILAST™ Technology.
The combination of two wear reducing materials, proprietary OXINIUM™ alloy
and a highly cross-linked plastic liner, VERILAST Technology significantly
reduces implant wear compared to traditional bearing couples on the market.
On traditional plastic liners, laboratory testing has demonstrated that
OXINIUM material is 4,900 times more abrasion resistant than cobalt chrome^2
and reduces knee replacement wear on traditional liners by up to 85-percent
compared to cobalt chrome components.^3

Editor's note

According to the Centers for Disease Control and Prevention, approximately
700,000 total knee replacements are performed in the US every year.

About Smith & Nephew

Smith & Nephew is a global medical technology business dedicated to helping
healthcare professionals improve people's lives. With leadership positions in
Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and
Trauma & Extremities, Smith & Nephew has around 11,000 employees and a
presence in more than 90 countries. Annual sales in 2013 were more than $4.3
billion. Smith & Nephew is a member of the FTSE100 (LSE: SN, NYSE: SNN).

For more information about Smith & Nephew, please visit our corporate website, follow @SmithNephewplc on Twitter or visit
SmithNephewplc on

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove
accurate. For example, statements regarding expected revenue growth and
trading margins, market trends and our product pipeline are forward-looking
statements. Phrases such as "aim", "plan", "intend", "anticipate",
"well-placed", "believe", "estimate", "expect", "target", "consider" and
similar expressions are generally intended to identify forward-looking
statements. Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual results to
differ materially from what is expressed or implied by the statements. For
Smith & Nephew, these factors include: economic and financial conditions in
the markets we serve, especially those affecting health care providers, payers
and customers; price levels for established and innovative medical devices;
developments in medical technology; regulatory approvals, reimbursement
decisions or other government actions; product defects or recalls; litigation
relating to patent or other claims; legal compliance risks and related
investigative, remedial or enforcement actions; strategic actions, including
acquisitions and dispositions, our success in performing due diligence,
valuing and integrating acquired businesses; disruption that may result from
transactions or other changes we make in our business plans or organisation to
adapt to market developments; and numerous other matters that affect us or our
markets, including those of a political, economic, business, competitive or
reputational nature. Please refer to the documents that Smith & Nephew has
filed with the U.S. Securities and Exchange Commission under the U.S.
Securities Exchange Act of 1934, as amended, including Smith & Nephew's most
recent annual report on Form 20-F, for a discussion of certain of these
factors. Any forward-looking statement is based on information available to
Smith & Nephew as of the date of the statement. All written or oral
forward-looking statements attributable to Smith & Nephew are qualified by
this caution. Smith & Nephew does not undertake any obligation to update or
revise any forward-looking statement to reflect any change in circumstances or
in Smith & Nephew's expectations.

™Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark

^1Catani F, Ensini A, Belvedere C, Feliciangeli A, Benedetti MG, Leardini A,
Giannini S. In vivo kinematics and kinetics of a bi-cruciate substituting
total knee arthroplasty: a combined fluoroscopic and gait analysis study. J
Orthop Res. 2009 Dec;27(12):1569-75.

^2G. Hunter and M. Long, "Abrasive wear of oxidized Zr-2.5Nb, CoCrMo, and
Ti-6Al-4V against bone cement", 6th World Biomaterials Cong. Trans., Society
For Biomaterials, Minneapolis, MN, 2000, p. 835.

^3M. Spector, M.D. Ries, R.B. Bourne, W.S. Sauer, M. Long, and G. Hunter, Wear
performance of ultra-high molecular weight polyethylene on oxidized zirconium
total knee femoral components, J. Bone Joint Surg., 83-A (S2), 2001, pp.


SOURCE Smith & Nephew

Contact: Investors, Phil Cowdy, Smith & Nephew, +44 (0) 20 7401 7646, Media,
Andrew Burns, Smith & Nephew, (901) 399-5739
Press spacebar to pause and continue. Press esc to stop.